{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:37:25Z","timestamp":1793450245710,"version":"4.5.0"},"reference-count":161,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004610","name":"Science and Technology Support Program of Jiangsu Province","doi-asserted-by":"publisher","award":["JSTJ-2025-128"],"award-info":[{"award-number":["JSTJ-2025-128"]}],"id":[{"id":"10.13039\/501100004610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52233007"],"award-info":[{"award-number":["52233007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFB3800900"],"award-info":[{"award-number":["2021YFB3800900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008868","name":"Jiangsu Province Department of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008868","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010881","name":"Suzhou City Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010881","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["SBK20250405084"],"award-info":[{"award-number":["SBK20250405084"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018556","name":"Science and Technology Program of Suzhou","doi-asserted-by":"publisher","award":["SYW2025195"],"award-info":[{"award-number":["SYW2025195"]}],"id":[{"id":"10.13039\/501100018556","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jconrel.2025.114379","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T15:45:01Z","timestamp":1762011901000},"page":"114379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"P2","title":["In vivo nano-engineering T cells for CAR-T therapy"],"prefix":"10.1016","volume":"388","author":[{"given":"Tianyu","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changchang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongzhe","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congcong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.114379_bb0005","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccell.2022.10.016","article-title":"Engineered T cell therapy for viral and non-viral epithelial cancers","volume":"41","author":"Norberg","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2025.114379_bb0010","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/s41467-024-45221-2","article-title":"CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes","volume":"15","author":"Jilani","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114379_bb0015","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.114379_bb0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-024-01792-6","article-title":"A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma","volume":"9","author":"Zhu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2025.114379_bb0025","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0030","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","article-title":"A guide to manufacturing CAR T cell therapies","volume":"53","author":"Vormittag","year":"2018","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0035","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.114379_bb0040","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1182\/blood-2022-155603","article-title":"Real-world impact of time from leukapheresis to infusion (vein-to-vein time) in patients with relapsed or refractory (r\/r) large b-cell lymphoma (LBCL) treated with axicabtagene ciloleucel","volume":"140","author":"Locke","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.114379_bb0045","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1042\/BST20150240","article-title":"Commercialization of cellular immunotherapies for cancer","volume":"44","author":"Walker","year":"2016","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.jconrel.2025.114379_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113891","article-title":"Nanotechnology-based delivery of CRISPR\/Cas9 for cancer treatment","volume":"176","author":"Xu","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.114379_bb0055","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","article-title":"Direct in vivo CAR T cell engineering","volume":"45","author":"Short","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2025.114379_bb0060","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.jconrel.2025.114379_bb0065","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.114379_bb0070","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2025.114379_bb0075","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","article-title":"In vivo CAR engineering for immunotherapy","volume":"25","author":"Li","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0080","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2025.114379_bb0085","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2025.114379_bb0090","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-O","article-title":"The cytoplasmic domain of the t-cell receptor zeta-chain is sufficient to couple to receptor-associated signal transduction pathways","volume":"64","author":"Irving","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2025.114379_bb0095","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2025.114379_bb0100","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0105","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114379_bb0110","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0115","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.114379_bb0120","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm827","article-title":"Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15","volume":"9","author":"Brentjens","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.114379_bb0125","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/00001622-199811000-00010","article-title":"Costimulatory approaches to adoptive immunotherapy","volume":"10","author":"Liebowitz","year":"1998","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0130","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0135","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2025.114379_bb0140","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2025.114379_bb0145","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2025.114379_bb0150","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0155","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.114379_bb0160","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2025.114379_bb0165","doi-asserted-by":"crossref","first-page":"17372","DOI":"10.1073\/pnas.0608138103","article-title":"Gene transfer in humans using a conditionally replicating lentiviral vector","volume":"103","author":"Levine","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2025.114379_bb0170","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/2159-8290.CD-NB2017-155","article-title":"FDA approves second CAR T-cell therapy","volume":"8","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2025.114379_bb0175","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0180","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002907","article-title":"CAR T cells for treating autoimmune diseases","volume":"9","author":"Blache","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jconrel.2025.114379_bb0185","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.114379_bb0190","article-title":"Minimally modified off-the-shelf allogeneic CAR T cells","volume":"32","author":"Loos","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0195","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40164-025-00654-3","article-title":"Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer","volume":"14","author":"Lyu","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0200","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1021\/acsmaterialsau.3c00032","article-title":"Lipid-based nanoparticles for drug\/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development","volume":"3","author":"Mehta","year":"2023","journal-title":"ACS Mater. Au"},{"key":"10.1016\/j.jconrel.2025.114379_bb0205","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41467-018-02929-2","article-title":"Supramolecular aptamer nano-constructs for receptor-mediated targeting and light-triggered release of chemotherapeutics into cancer cells","volume":"9","author":"Prusty","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114379_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115042","article-title":"Engineering nanoparticle toolkits for mRNA delivery","volume":"200","author":"Sun","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.114379_bb0215","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/s12951-024-02648-5","article-title":"Recent advances in gene delivery nanoplatforms based on spherical nucleic acids","volume":"22","author":"Valatabar","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103628","article-title":"New advances in exosome-based targeted drug delivery systems","volume":"172","author":"Ferreira","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0225","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1039\/D1MH01969D","article-title":"Tumor-targeted nano-delivery system of therapeutic RNA","volume":"9","author":"Wang","year":"2022","journal-title":"Mater. Horiz."},{"key":"10.1016\/j.jconrel.2025.114379_bb0230","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.3390\/ma14226812","article-title":"Polymer-based nanosystems-a versatile delivery approach","volume":"14","author":"Niculescu","year":"2021","journal-title":"Materials (Basel)"},{"key":"10.1016\/j.jconrel.2025.114379_bb0235","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bmt.2023.09.001","article-title":"Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment","volume":"5","author":"Elumalai","year":"2024","journal-title":"Biomed. Tech."},{"key":"10.1016\/j.jconrel.2025.114379_bb0240","doi-asserted-by":"crossref","first-page":"352","DOI":"10.20892\/j.issn.2095-3941.2021.0004","article-title":"Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development","volume":"18","author":"Liang","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.jconrel.2025.114379_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2023.100165","article-title":"Lipid polymer hybrid nanoparticles as potent vehicles for drug delivery in cancer therapeutics","volume":"20","author":"Parveen","year":"2023","journal-title":"Med. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.114379_bb0250","doi-asserted-by":"crossref","DOI":"10.1002\/sstr.202100026","article-title":"Improving the delivery of drugs and nucleic acids to t cells using nanotechnology","volume":"2","author":"Lou","year":"2021","journal-title":"Small Struct."},{"key":"10.1016\/j.jconrel.2025.114379_bb0255","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3390\/nano11030746","article-title":"Nanoplatforms for targeted stimuli-responsive drug delivery: a review of platform materials and stimuli-responsive release and targeting mechanisms","volume":"11","author":"Sun","year":"2021","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.jconrel.2025.114379_bb0260","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.addr.2020.06.005","article-title":"Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers","volume":"157","author":"Fang","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.114379_bb0265","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41563-019-0566-2","article-title":"The entry of nanoparticles into solid tumours","volume":"19","author":"Sindhwani","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2025.114379_bb0270","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2025.114379_bb0275","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jconrel.2015.12.049","article-title":"Water soluble PEG-conjugate of xanthine oxidase inhibitor, PEG-AHPP micelles, as a novel therapeutic for ROS related inflammatory bowel diseases","volume":"223","author":"Fang","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114379_bb0280","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jconrel.2019.11.008","article-title":"Nanomedicine - advantages for their use in rheumatoid arthritis theranostics","volume":"316","author":"Xiao","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114379_bb0285","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41569-021-00629-x","article-title":"Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis","volume":"19","author":"Chen","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0290","doi-asserted-by":"crossref","first-page":"8073","DOI":"10.7150\/thno.37198","article-title":"Alliance with EPR effect: combined strategies to improve the EPR effect in the tumor microenvironment","volume":"9","author":"Park","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2025.114379_bb0295","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3390\/jpm11060571","article-title":"Recent advances in tumor targeting via EPR effect for cancer treatment","volume":"11","author":"Subhan","year":"2021","journal-title":"J. Pers Med."},{"key":"10.1016\/j.jconrel.2025.114379_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114614","article-title":"The tumor EPR effect for cancer drug delivery: current status, limitations, and alternatives","volume":"191","author":"Sun","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.114379_bb0305","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.jconrel.2025.114379_bb0310","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2025.114379_bb0315","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jconrel.2017.05.019","article-title":"Alexander, recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer\u2019s disease","volume":"260","author":"Agrawal","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114379_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114234","article-title":"Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins","volume":"184","author":"Pardridge","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.114379_bb0325","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1671761","article-title":"In vivo generated human CAR T cells eradicate tumor cells","volume":"8","author":"Agarwal","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2025.114379_bb0330","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.4049\/jimmunol.1500956","article-title":"Exclusive transduction of human CD4+ T cells upon systemic delivery of CD4-targeted lentiviral vectors","volume":"195","author":"Zhou","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0335","first-page":"5702","article-title":"Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors","volume":"4","author":"Frank","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.jconrel.2025.114379_bb0340","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood.2024024523","article-title":"In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand","volume":"144","author":"Nicolai","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.114379_bb0345","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-021-00508-1","article-title":"AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia","volume":"11","author":"Nawaz","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jconrel.2025.114379_bb0350","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1016\/j.ymthe.2021.06.004","article-title":"Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs","volume":"29","author":"Tombacz","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2025.114379_bb0355","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2025.114379_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102518","article-title":"In situ engineering of mRNA-CAR T cells using spleen-targeted ionizable lipid nanoparticles to eliminate cancer cells","volume":"59","author":"Li","year":"2024","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2025.114379_bb0365","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0370","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114379_bb0375","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1007\/s11095-009-9853-y","article-title":"Cell type-specific targeting with surface-engineered lentiviral vectors co-displaying OKT3 antibody and fusogenic molecule","volume":"26","author":"Yang","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2025.114379_bb0380","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1182\/blood-2012-02-412973","article-title":"T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing","volume":"120","author":"Zhou","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.114379_bb0385","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809158","article-title":"In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome","volume":"10","author":"Pfeiffer","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jconrel.2025.114379_bb0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079047","article-title":"CD19 and CD20 targeted vectors induce minimal activation of resting B lymphocytes","volume":"8","author":"Kneissl","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2025.114379_bb0395","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1038\/mt.2010.178","article-title":"Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy","volume":"18","author":"Frecha","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2025.114379_bb0400","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1038\/nm.2964","article-title":"SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells","volume":"18","author":"Baldauf","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.114379_bb0405","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006292","article-title":"Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering","volume":"11","author":"Michels","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2025.114379_bb0410","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.114379_bb0415","doi-asserted-by":"crossref","DOI":"10.1002\/biot.201900286","article-title":"Adeno-associated viral vectors for homology-directed generation of CAR-T cells","volume":"15","author":"Moco","year":"2020","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.jconrel.2025.114379_bb0420","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","article-title":"Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering","volume":"20","author":"Billingsley","year":"2020","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2025.114379_bb0425","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1021\/acs.nanolett.1c02503","article-title":"Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells","volume":"22","author":"Billingsley","year":"2022","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2025.114379_bb0430","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.addr.2020.06.017","article-title":"Lipid-based nanoparticle technologies for liver targeting","volume":"154\u2013155","author":"Bottger","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.114379_bb0435","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.114379_bb0440","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-021-01573-6","article-title":"A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against chikungunya virus","volume":"27","author":"August","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.114379_bb0445","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2025.114379_bb0450","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ymthe.2024.01.005","article-title":"The landscape of nanoparticle-based siRNA delivery and therapeutic development","volume":"32","author":"Moazzam","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2025.114379_bb0455","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1039\/D1CS00617G","article-title":"Emerging mRNA technologies: delivery strategies and biomedical applications","volume":"51","author":"Xiao","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2025.114379_bb0460","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202303261","article-title":"Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy","volume":"35","author":"Zong","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2025.114379_bb0465","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12951-022-01478-7","article-title":"Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects","volume":"20","author":"Kiaie","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0470","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3390\/biomedicines9050530","article-title":"Non-immunotherapy application of LNP-mRNA: maximizing efficacy and safety","volume":"9","author":"Vlatkovic","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jconrel.2025.114379_bb0475","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg1036","article-title":"A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium","volume":"9","author":"Kon","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2025.114379_bb0480","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","article-title":"Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo","volume":"350","author":"Zhou","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114379_bb0485","article-title":"Antigen presenting cell mimetic lipid nanoparticles for rapid mRNA CAR T cell cancer immunotherapy","volume":"36","author":"Metzloff","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2025.114379_bb0490","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202304378","article-title":"In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism","volume":"20","author":"Billingsley","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2025.114379_bb0495","doi-asserted-by":"crossref","first-page":"10761","DOI":"10.1021\/ja0015388","article-title":"Degradable poly(\u03b2-amino esters): Synthesis, characterization, and self-assembly with plasmid DNA","volume":"122","author":"Lynn","year":"2000","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2025.114379_bb0500","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.omtn.2023.04.019","article-title":"Poly(beta-amino ester)s-based nanovehicles: structural regulation and gene delivery","volume":"32","author":"Zhang","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2025.114379_bb0505","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.3390\/pharmaceutics14102236","article-title":"Extracellular vesicles as delivery vehicles for therapeutic nucleic acids in cancer gene therapy: progress and challenges","volume":"14","author":"Du","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.114379_bb0510","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.ymthe.2023.01.021","article-title":"Extracellular vesicles: the next generation in gene therapy delivery","volume":"31","author":"Cecchin","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2025.114379_bb0515","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nbt.1807","article-title":"Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes","volume":"29","author":"Alvarez-Erviti","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0520","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/mt.2012.180","article-title":"Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells","volume":"21","author":"Ohno","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2025.114379_bb0525","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2025.114379_bb0530","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41551-023-01142-x","article-title":"Genetically encoding multiple functionalities into extracellular vesicles for the targeted delivery of biologics to T cells","volume":"8","author":"Stranford","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2025.114379_bb0535","doi-asserted-by":"crossref","first-page":"16413","DOI":"10.1021\/jacs.8b10047","article-title":"Reprogramming exosomes as nanoscale controllers of cellular immunity","volume":"140","author":"Cheng","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2025.114379_bb0540","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau6085","article-title":"Structure and function of the immune system in the spleen","volume":"4","author":"Lewis","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0545","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jconrel.2023.05.009","article-title":"Recent advances in biomimetic nanodelivery systems: new brain-targeting strategies","volume":"358","author":"Liao","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114379_bb0550","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1021\/mp400054e","article-title":"Biodistribution and pharmacokinetics of EGFR-targeted thiolated gelatin nanoparticles following systemic administration in pancreatic tumor-bearing mice","volume":"10","author":"Xu","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.114379_bb0555","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1084\/jem.20131142","article-title":"CCR7 provides localized access to IL-2 and defines homeostatically distinct regulatory T cell subsets","volume":"211","author":"Smigiel","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2025.114379_bb0560","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3390\/pharmaceutics14061132","article-title":"Micro\/nanosystems for magnetic targeted delivery of bioagents","volume":"14","author":"Garello","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.114379_bb0565","doi-asserted-by":"crossref","first-page":"15339","DOI":"10.1039\/C8NR03976C","article-title":"Systemic siRNA delivery to tumors by cell-penetrating alpha-helical polypeptide-based metastable nanoparticles","volume":"10","author":"Liu","year":"2018","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2025.114379_bb0570","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307813120","article-title":"Thiophene-based lipids for mRNA delivery to pulmonary and retinal tissues","volume":"121","author":"Eygeris","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2025.114379_bb0575","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2025.2544688","article-title":"Impact of PEGylation and hyaluronan functionalization on lipoplex-mediated mRNA delivery to the canine retina","volume":"32","author":"Appelbaum","year":"2025","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2025.114379_bb0580","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0585","article-title":"Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging","volume":"6","author":"Zhang","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.jconrel.2025.114379_bb0590","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2311276120","article-title":"Biomimetic noncationic lipid nanoparticles for mRNA delivery","volume":"120","author":"Wang","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2025.114379_bb0595","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1039\/D3MH02066E","article-title":"A polyamino acid-based phosphatidyl polymer library for in vivo mRNA delivery with spleen targeting ability","volume":"11","author":"Zhao","year":"2024","journal-title":"Mater. Horiz."},{"key":"10.1016\/j.jconrel.2025.114379_bb0600","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/s41565-024-01727-w","article-title":"Polymersomes with splenic avidity target red pulp myeloid cells for cancer immunotherapy","author":"Wauters","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0605","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1039\/C9MH01669D","article-title":"Twenty-five years of polymersomes: lost in translation?","volume":"7","author":"Matoori","year":"2020","journal-title":"Mater. Horiz."},{"key":"10.1016\/j.jconrel.2025.114379_bb0610","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jconrel.2011.10.005","article-title":"Polymersomes for drug delivery: design, formation and characterization","volume":"161","author":"Lee","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114379_bb0615","article-title":"Tuning the organ tropism of polymersome for spleen-selective nanovaccine delivery to boost cancer immunotherapy","volume":"35","author":"Gu","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2025.114379_bb0620","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2174\/138945008784533570","article-title":"Transgenic models in allergic responses","volume":"9","author":"Hausding","year":"2008","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.jconrel.2025.114379_bb0625","doi-asserted-by":"crossref","first-page":"13740","DOI":"10.1038\/s41598-020-70793-6","article-title":"A novel approach to genetic engineering of T-cell subsets by hematopoietic stem cell infection with a bicistronic lentivirus","volume":"10","author":"Bogert","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2025.114379_bb0630","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/1521-2254(200011\/12)2:6<416::AID-JGM142>3.0.CO;2-Y","article-title":"T cell-specific expression from Mo-MLV retroviral vectors containing a CD4 mini-promoter\/enhancer","volume":"2","author":"Zhao-Emonet","year":"2000","journal-title":"J. Gene Med."},{"key":"10.1016\/j.jconrel.2025.114379_bb0635","article-title":"CD38-specific CAR integrated into CD38 locus driven by different promoters causes distinct antitumor activities of T and NK cells","volume":"10","author":"Liao","year":"2023","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.jconrel.2025.114379_bb0640","doi-asserted-by":"crossref","DOI":"10.1002\/biot.202200062","article-title":"Engineering of the CMV promoter for controlled expression of recombinant genes in HEK293 cells","volume":"17","author":"Johari","year":"2022","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.jconrel.2025.114379_bb0645","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fphar.2015.00095","article-title":"Improving the safety of cell therapy with the TK-suicide gene","volume":"6","author":"Greco","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0650","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-023-01439-z","article-title":"The notch signaling pathway: a potential target for cancer immunotherapy","volume":"16","author":"Li","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0655","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12943-019-1057-4","article-title":"Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity","volume":"18","author":"Yu","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2025.114379_bb0660","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jcyt.2025.02.007","article-title":"Synthetic receptor-based cell therapies for autoimmune diseases: an update","volume":"27","author":"Lachota","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jconrel.2025.114379_bb0665","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41434-021-00254-w","article-title":"CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free sleeping beauty gene transfer to treat multiple myeloma","volume":"28","author":"Prommersberger","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2025.114379_bb0670","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011759","article-title":"T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles","volume":"13","author":"Bimbo","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2025.114379_bb0675","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.3390\/ijms22105084","article-title":"Contemporary transposon tools: a review and guide through mechanisms and applications of sleeping beauty, piggybac and tol2 for genome engineering","volume":"22","author":"Sandoval-Villegas","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2025.114379_bb0680","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0685","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2023-181855","article-title":"Bio-orthogonally redirected bispecific lentiviral vectors for in vivo CAR-T cell generation","volume":"142","author":"Mei","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.114379_bb0690","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002737","article-title":"Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells","volume":"9","author":"Huckaby","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2025.114379_bb0695","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1182\/blood-2023-182195","article-title":"Vivovec\u2122 surface-engineered lentiviral particles mediate in vivo CAR T generation with potent and highly durable activity in non-human primates and tumor-bearing humanized mice","volume":"142","author":"Parker","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.114379_bb0700","first-page":"2085","article-title":"In vivo HSC prime editing rescues sickle cell disease in a mouse model","volume":"141","author":"Li","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.114379_bb0705","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus","author":"Wang","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.114379_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jconrel.2025.114379_bb0715","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.114379_bb0720","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.apsb.2019.10.002","article-title":"Comparative study of mucoadhesive and mucus-penetrative nanoparticles based on phospholipid complex to overcome the mucus barrier for inhaled delivery of baicalein","volume":"10","author":"Dong","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2025.114379_bb0725","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.114379_bb0730","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","article-title":"B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome","volume":"19","author":"Fridman","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0735","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.4049\/jimmunol.0903009","article-title":"B cells are required for optimal CD4 and CD8 T cell tumor immunity: therapeutic b cell depletion enhances B16 melanoma growth in mice","volume":"184","author":"DiLillo","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0740","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/blood-2002-02-0578","article-title":"Specific transgene expression in human and mouse CD4+ cells using lentiviral vectors with regulatory sequences from the CD4 gene","volume":"101","author":"Marodon","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.114379_bb0745","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1074-7613(00)80375-1","article-title":"An enhancer that directs lineage-specific expression of CD8 in positively selected thymocytes and mature T cells","volume":"7","author":"Ellmeier","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2025.114379_bb0750","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.coi.2015.06.015","article-title":"Synthetic biology approaches to engineer T cells","volume":"35","author":"Wu","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0755","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","article-title":"mRNA-based cancer therapeutics","volume":"23","author":"Liu","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2025.114379_bb0760","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12943-021-01348-0","article-title":"mRNA therapeutics in cancer immunotherapy","volume":"20","author":"Beck","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2025.114379_bb0765","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00262-014-1572-5","article-title":"A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor","volume":"63","author":"Krug","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2025.114379_bb0770","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nm.4313","article-title":"Refining strategies to translate genome editing to the clinic","volume":"23","author":"Cornu","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.114379_bb0775","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.114379_bb0780","doi-asserted-by":"crossref","DOI":"10.1002\/wsbm.1408","article-title":"Immunity to CRISPR Cas9 and Cas12a therapeutics","volume":"10","author":"Chew","year":"2018","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"10.1016\/j.jconrel.2025.114379_bb0785","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1016\/j.ymthe.2022.09.015","article-title":"AAV vectors: the Rubik\u2019s cube of human gene therapy","volume":"30","author":"Pupo","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2025.114379_bb0790","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jconrel.2025.114379_bb0795","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1635159","article-title":"Smart CAR-T Nanosymbionts: archetypes and proto-models","volume":"16","author":"Baena","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0800","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-018-0568-6","article-title":"Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward","volume":"11","author":"Li","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2025.114379_bb0805","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/jha2.333","article-title":"Chimeric antigen receptor T-cell therapy: challenges and framework of outpatient administration","volume":"3","author":"Gatwood","year":"2022","journal-title":"EJHaem"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925009939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925009939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:58:06Z","timestamp":1780822686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925009939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":161,"alternative-id":["S0168365925009939"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114379","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo nano-engineering T cells for CAR-T therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114379","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114379"}}